0000000000283005

AUTHOR

Universitat Autònoma De Barcelona. Departament De Medicina

showing 2 related works from this author

Coronary Revascularization and Long-Term Survivorship in Chronic Coronary Syndrome

2021

Ischemic heart disease (IHD) persists as the leading cause of death in the Western world. In recent decades, great headway has been made in reducing mortality due to IHD, based around secondary prevention. The advent of coronary revascularization techniques, first coronary artery bypass grafting (CABG) surgery in the 1960s and then percutaneous coronary intervention (PCI) in the 1970s, has represented one of the major breakthroughs in medicine during the last century. The benefit provided by these techniques, especially PCI, has been crucial in lowering mortality rates in acute coronary syndrome (ACS). However, in the setting where IHD is most prevalent, namely chronic coronary syndrome (CC…

medicine.medical_specialtyAcute coronary syndromeIschemic heart diseasemedicine.medical_treatmentstress cardiac magnetic resonancelcsh:MedicineChronic coronary syndromeReviewischemiaDisease030204 cardiovascular system & hematologyRevascularizationCoronary artery diseaseCoronary artery disease03 medical and health sciences0302 clinical medicineIschemiaInternal medicineMedicine030212 general & internal medicineCause of deathStress cardiac magnetic resonancechronic coronary syndromebusiness.industryMortality ratelcsh:RPercutaneous coronary interventionGeneral Medicinemedicine.diseaseischemic heart diseaseMyocardial revascularizationmyocardial revascularizationConventional PCICardiologybusinesscoronary artery diseaseJournal of Clinical Medicine
researchProduct

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Thera…

2022

Simple Summary We present the long-term results of patients receiving allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory mantle cell lymphoma (R/R MCL) in the last 25 years in Spain. We conclude that allo-SCT may be a curative option in R/R MCL with a low cumulative incidence (CI) of relapse, although non-relapse mortality (NRM) is still high, which is mainly secondary to acute graft-versus-host disease (aGVHD). Results are better for fit patients, using HLA-identical (related or unrelated) or haploidentical related donors and without previous ASCT. However, the arrival of new highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegat…

CAR-T cell therapyCancer ResearchLimfomesMantle cell lymphomaAcute graft-versus-host diseaseTransplantation of organstarget therapyacute graft-versus-host diseasemantle cell lymphomaTarget therapyTrasplantament d'òrgansgraft-versus-lymphoma effectnon-relapse mortalityOncologyNon-relapse mortalityimmune system diseaseshemic and lymphatic diseasesallogeneic stem-cell transplantationmantle cell lymphoma; allogeneic stem-cell transplantation; non-relapse mortality; acute graft-versus-host disease; graft-versus-lymphoma effect; target therapy; CAR-T cell therapyLymphomasAllogeneic stem-cell transplantationCàncerGraft-versus-lymphoma effect
researchProduct